Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:MRUS NASDAQ:NRIX NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$38.75-4.1%$41.12$16.50▼$48.45$3.76BN/A10,725 shs18,112 shsMRUSMerus$67.13-2.1%$63.45$33.19▼$69.20$5.18B1.19551,409 shs391,593 shsNRIXNurix Therapeutics$8.95-2.7%$10.80$8.18▼$29.56$703.33M2.1732,325 shs713,377 shsRAREUltragenyx Pharmaceutical$31.29-0.7%$30.04$25.81▼$60.37$3.04B0.211.27 million shs1.91 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-4.08%-6.20%-3.22%+21.02%+3,874,999,900.00%MRUSMerus-2.07%+0.77%+3.92%+21.20%+35.12%NRIXNurix Therapeutics-2.72%-5.39%-7.25%-25.17%-63.35%RAREUltragenyx Pharmaceutical-0.67%-0.82%+14.24%-20.36%-43.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$38.75-4.1%$41.12$16.50▼$48.45$3.76BN/A10,725 shs18,112 shsMRUSMerus$67.13-2.1%$63.45$33.19▼$69.20$5.18B1.19551,409 shs391,593 shsNRIXNurix Therapeutics$8.95-2.7%$10.80$8.18▼$29.56$703.33M2.1732,325 shs713,377 shsRAREUltragenyx Pharmaceutical$31.29-0.7%$30.04$25.81▼$60.37$3.04B0.211.27 million shs1.91 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-4.08%-6.20%-3.22%+21.02%+3,874,999,900.00%MRUSMerus-2.07%+0.77%+3.92%+21.20%+35.12%NRIXNurix Therapeutics-2.72%-5.39%-7.25%-25.17%-63.35%RAREUltragenyx Pharmaceutical-0.67%-0.82%+14.24%-20.36%-43.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AMRUSMerus 3.08Buy$88.7532.21% UpsideNRIXNurix Therapeutics 2.88Moderate Buy$29.07224.82% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50160.47% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, RARE, AAPG, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.008/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025MRUSMerusIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.008/25/2025MRUSMerusAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$90.008/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/6/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$97.00 ➝ $96.008/6/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$112.00 ➝ $105.007/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$80.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M26.81N/AN/A$0.48 per share80.73MRUSMerus$36.13M140.52N/AN/A$9.46 per share7.10NRIXNurix Therapeutics$54.55M12.54N/AN/A$7.44 per share1.20RAREUltragenyx Pharmaceutical$560.23M5.38N/AN/A$2.76 per share11.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AMRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)NRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)Latest NRIX, RARE, AAPG, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53MRUSMerusN/A8.398.39NRIXNurix TherapeuticsN/A6.826.82RAREUltragenyx PharmaceuticalN/A2.452.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AMRUSMerus96.14%NRIXNurix TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AMRUSMerus3.70%NRIXNurix Therapeutics7.40%RAREUltragenyx Pharmaceutical5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60092.96 millionN/AN/AMRUSMerus3775.63 million72.84 millionOptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableNRIX, RARE, AAPG, and MRUS HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Fred Alger Management LLC2 hours ago | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10 at 1:07 PM | seekingalpha.comCantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)September 9 at 4:54 PM | theglobeandmail.comUltragenyx Reports Positive Phase 3 Gene Therapy ResultsSeptember 9 at 4:54 PM | msn.comRARE Reports Positive Long-Term Data From Metabolic Disorder StudySeptember 9 at 12:16 PM | zacks.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Alliancebernstein L.P.September 9 at 4:57 AM | marketbeat.comUltragenyx Pharmaceutical Inc. Reports Positive Phase 3 Results for DTX401 Gene Therapy in Glycogen Storage Disease Type Ia with Significant Reductions in Cornstarch Intake and Improved Glycemic ControlSeptember 8 at 4:31 PM | quiverquant.comQUltragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)September 8 at 4:18 PM | globenewswire.comParkman Healthcare Partners LLC Has $11.02 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 8 at 7:45 AM | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Cinctive Capital Management LPSeptember 7, 2025 | marketbeat.comCubist Systematic Strategies LLC Makes New Investment in Ultragenyx Pharmaceutical Inc. $RARESeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Lowers Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comCutter Capital Management LP Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Grows Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 6, 2025 | marketbeat.comAssessing Ultragenyx Pharmaceutical: Insights From 8 Financial AnalystsSeptember 6, 2025 | benzinga.comAdage Capital Partners GP L.L.C. Has $77.82 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARESeptember 5, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 6.5% - Still a Buy?September 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comFirst Light Asset Management LLC Cuts Position in Ultragenyx Pharmaceutical Inc. $RARESeptember 4, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Increases Stake in Ultragenyx Pharmaceutical Inc. $RARESeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials Stock Rides Rare Earth Boom to New HighsBy Gabriel Osorio-Mazilli | August 12, 2025NRIX, RARE, AAPG, and MRUS Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$38.75 -1.65 (-4.08%) As of 09/10/2025 03:55 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Merus NASDAQ:MRUS$67.13 -1.42 (-2.07%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$68.35 +1.22 (+1.82%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Nurix Therapeutics NASDAQ:NRIX$8.95 -0.25 (-2.72%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$8.96 +0.01 (+0.06%) As of 06:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Ultragenyx Pharmaceutical NASDAQ:RARE$31.29 -0.21 (-0.67%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$32.28 +0.99 (+3.18%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
